Activation-independent nuclear translocation of mitogen activated protein kinase ERK1 mediated by thiol-modifying chemicals  by Meili, Ruedi & Ballmer-Hofer, Kurt
FEBS Letters 394 (1996) 34-38 FEBS 17533 
Activation-independent uclear translocation of mitogen activated 
protein kinase ERK1 mediated by thiol-modifying chemicals 
Ruedi Meili, Kurt Ballmer-Hofer* 
Friedrich Miescher Institute, P.O. Box 2543, CH-4002 Basel, Switzerland 
Received 2 August 1996 
Abstract The extracellular signal-regulated kinases ERK1 and 
ERK2 are key mediators of mitogenic signals in most cell types. 
In fibroblasts, sustained activation and nuclear translocation are 
mandatory for S-phase induction. The events leading to 
activation of these kinases are well understood, whereas little is 
known about the mechanism of their translocation. Using 
indirect immnnoflnorescence and biochemical analysis we show 
that ERK1 can translocate to the nucleus in the absence of 
activation and phosphorylation by upstream kinases when cells 
are treated with thiol-modifying chemicals. We propose that 
these chemicals inactivate a protein contributing to the 
cytoplasmic localization of ERK1. 
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1. Introduction 
An important part of the cellular response to a changing 
environment is adjusting the levels of gene products to new 
conditions. To initiate these adaptations, signals have to be 
relayed from the plasma membrane to the nucleus. 
A kinase early implicated in the transduction of these sig- 
nals [1] was later dubbed extracellular signal-regulated kinase 
(ERK). Two closely related isoforms, ERK1 and ERK2 are 
found in mammalian cells which seem to be functionally 
equivalent in most aspects. Following activation, transloca- 
tion of ERK from the cytoplasm to the nucleus has been 
observed in many cell systems [2-6]. 
The extent of translocation seems to determine the response 
of a cell to the signalling event. In fibroblasts, only stimuli 
which lead to detectable nuclear localization of ERK are mi- 
togenic while in PCI2 rat pheocytochroma cells mitogenesis 
can occur without apparent ranslocation of ERK to the nu- 
cleus. Instead, a correlation exists between differentiation of 
PC12 cells and detectable nuclear localization of ERK (re- 
viewed in [7]). 
ERK becomes activated by a chain of interacting proteins. 
At the plasma membrane, receptor activation results in the 
conversion of the small GTP binding protein Ras from the 
GDP-bound, inactive to the GTP-bound, active form via in- 
termediary proteins. The signal transducing proteins involved 
vary depending on the external stimuli and the receptors en- 
gaged (reviewed in [8]). 
Activated Ras recruits the serine/threonine kinase Raf  to 
the plasma membrane [9,10] where Raf  is fully activated by 
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additional phosphorylation [11]. Raf  then phosphorylates and 
activates MEK (for MAPK/ERK kinase). MEK is a dual 
specificity kinase which in turn activates ERK by phosphor- 
ylation of a threonine and a tyrosine residue. The three ki- 
nases Raf, MEK and ERK together form a mitogen-activated 
protein kinase (MAPK) cascade (reviewed in [12]). The mech- 
anism responsible for nuclear translocation of ERK is un- 
known. 
Here we describe that several thiol-modifying chemicals in- 
duce nuclear translocation of ERK in the absence of its acti- 
vation. This implies that ERK activation and translocation 
are separable vents. 
2. Materials and methods 
2.1. Materials 
Diamide, phenylarsine oxide, myelin basic protein and sodium 
orthovanadate were obtained from Sigma. N-Ethylmaleimide 
(NEM), aprotinin, leupeptin, and nocodazole was purchased from 
Boehringer Mannheim. [~,-a2p]ATP was from ICN. 13-Glycerophos- 
phate and protein A-Sepharose CL-4B were obtained from Pharmacia 
Biotech Inc. 4',6-Diamidine-2'-phenylindole ihydrochloride (DAPI) 
for DNA staining was obtained from Serva. Taxol was purchased 
from Calbiochem. Recombinant B-chain homodimer platelet-derived 
growth factor was from Saxon Biochemicals GmbH. Secondary anti- 
bodies for Western blotting and immunofluorescence were purchased 
from Southern Biotechnology Associates. 
Vanadyl hydroperoxide was prepared [13] by mixing equivalent 
concentrations (10 mM) of orthovanadate and hydrogen peroxide 
followed by a 15 rain incubation at room temperature. To destroy 
unreacted hydrogen peroxide, catalase (200/.tg/ml) was added. 
2.2. Tissue culture 
REF52 cells were maintained in Dulbecco's modified Eagle medium 
(DMEM) supplemented with 10% fetal calf serum (GIBCO BRL). 
Growth arrest was achieved by culturing the cells in DMEM contain- 
ing 0.1% FCS for 48 h. 
2.3. Immunofluorescenee 
Subcellular localization of ERK1 in REF 52 cells was determined as 
described in [14] by indirect immunofluorescence using a polyclonal 
rabbit antibody raised against a C-terminal peptide of rat ERKI [15]. 
The antibody was purchased from Upstate Biotechnology Inc. (UBI). 
Phosphotyrosine was detected using the mouse monoclonal anti phos- 
photyrosine antibody 4GI0 [16]. Nuclei were stained with the DNA 
binding dye DAPI (0.1 ~tg/ml). 
2.4. Microinfl, ction 
REF52 cells were microinjected with the plasmid pCMV NARaf as 
described earlier [14]. This construct directs expression of a c-Rafl 
mutant lacking the kinase domain which acts on signalling in a domi- 
nant negative fashion [17] under the control of a cytomegalo virus 
early promoter. Expression of NARaf protein was detected by indirect 
immunofluorescence using a mouse monoclonal anti-c-Rafl antibody 
purchased from UBI. 
2.5. MAPkinase activity assay 
ERKl activity was measured in an immune complex kinase assay 
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using a rabbit polyclonal antibody specific for ERKI (FI5P) and 
myelin basic protein as a substrate as described previously [18]. 
2.6, Western analysis 
24 111 of lysates prepared in the same way as for ERK activity 
assays were added to 6 txl of 5 × concentrated SDS sample buffer, 
separated on 12.5% SDS PAGE and transferred to a PVDF mem- 
brane. The membranes were immunodecorated following standard 
Western blotting protocols: for ERK1 with the anti-ERK1 CT anti- 
body (UBI), for phosphotyrosine with the monoclonal antibody 4GI0 
and for MEKI with an antibody raised against a N-terminal peptide 
[19]. An alkaline phosphatase-linked s condary antibody (Southern 
Biotechnology Associates) was used. The membranes were developed 
using a colorigenic substrate combination (5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium, Boehringer Mannheim). 
3. Results 
3.1. Thiol-reactive chemicals induce relocalization of ERK1 to 
the nucleus 
Different chemicals were tested for their effect on the sub- 
cellular localization of ERK in a rat-embryo-derived fibro- 
blastic cell line, REF52 using indirect immunofluorescence. 
In growth-arrested cells (Fig. 1, panel A1) the fluorescence 
intensity in the nucleus was lower than in the adjacent cyto- 
plasm. As described previously [2,20], stimulation by mitogens 
for 10 rain (Fig. 1, panels A3 and A4) increased nuclear fluor- 
escence to a level equal to or higher than that of the surround- 
ing cytoplasm, indicating that ERK1 accumulated in the nu- 
cleus in response to mitogen stimulation. 
A 10-min treatment with membrane-permeable thiol-reac- 
rive compounds like phenylarsine oxide (PAO, 40 txM) (Fig. 1, 
panel A2), N-ethylmaleimide (NEM, 1 raM) (data not shown) 
or 250 laM diamide (data not shown) resulted in a nuclear 
localization of ERK1 which was indistinguishable from that 
induced by mitogens. The membrane impermeable sodium 
arsineoxide, which has a reactivity towards thiols like PAO, 
did not affect subcellular localization of ERK1 at concentra- 
tions of up to 1 mM (data not shown). This suggests that 
modifications of intracellular thiol groups mediate the effect 
of PAO on ERK1 localization. 
3.2. Thiol-reactive reagents neither activate nor promote 
phosphorylation of ERK 
Biochemical analysis was used to determine the effect of 
PAO on the activity and phosphorylation state of ERK1. 
An anti-phosphotyrosine W stern blot (Fig. 2A) of whole 
cell lysates demonstrated that PAO treatment (lane 2) did not 
change tyrosine phosphorylation i  comparison to growth-ar- 
rested cells (lane 1). Mitogen stimulation on the other hand 
led to an increase in the phosphorylation of discrete bands: 
PDGF (lane 3) promoted phosphorylation of the 180 kDa 
PDGF receptor and two other bands, which were identified 
as the phosphorylated forms of ERK1 and ERK2 by anti- 
ERK1 Western blotting (Fig. 2B). ERK1 and ERK2 were 
phosphorylated following serum stimulation as well (lane 4). 
When ERK1 or ERK2 are phosphorylated at either one of 
their two regulatory sites, reduced mobility in SDS PAGE is 
observed shifting the protein band to a higher apparent mo- 
lecular mass [21]. An anti-ERK1 Western blot (Fig. 2B) 
showed that PAO did not promote this shift (lane 2), indicat- 
ing that no phosphorylation ccurred while the expected shift 
was present following mitogen stimulation (Fig. 2B, lanes 3 
and 4). Cross-reactivity of the anti-ERK1 antibody with Rat 
ERK2 showed that changes of ERK2 mobility in response to 
the applied stimuli paralleled those observed for ERK1. Sa- 
tisfactory detection of ERK2 required loading of 10 times 
more lysate (data not shown). 
The absence of a shift in apparent molecular mass following 
PAO treatment indicated that ERKI was not activated by 
PAO. To confirm this, immune complex kinase assay of 
ERK1 with myelin basic protein as a substrate was per- 
formed. ERK1 isolated from PAO-treated cells was not acti- 
vated (Fig. 2C, lane 2) when compared to ERKI isolated 
from growth-arrested cells (Fig. 2C, lane 1), while ERKI iso- 
lated from PDGF-stimulated cells showed a 5-fold activation 
(Fig. 2C, lane 3). 
3.3. Induction of nuclear localization of ERK by PAO is not 
mediated by the MAPK cascade 
Since mitogen-induced nuclear localization of ERK corre- 
lates with the activation of the MAPK cascade, we investi- 
gated the role of Raf and MEK in PAO-induced nuclear 
localization. An expression vector coding for NARaf, a mu- 
tant known to block mitogenic signalling in a dominant neg- 
ative fashion [17], was microinjected into serum-starved cells. 
After further incubation for 6 h to allow for expression of the 
protein, cells were either stimulated by serum (Fig. 3A, left 
column) or treated with PAO (Fig. 3A, right column). NARaf 
expression was confirmed by staining the injected cells with an 
anti-c-Rafl antibody (Fig. 3A, lower row). Expression of the 
dominant negative mutant of Rafl blocked serum-induced 
nuclear localization of ERK1 but did not prevent nuclear 
localization induced by PAO (Fig. 3A, upper row). This in- 
dicates that the mechanism of PAO action is independent of 
Rafl activity while nuclear localization in response to mitogen 
stimulation requires Rafl. Since ERKs were not phosphory- 
lated in response to PAO, a contribution of MEK kinase 
activity to its effect seemed unlikely as well. To confirm this 
assumption a Western blot of cell lysates was decorated with 
an anti-MEKl antibody. As shown in Fig. 3B (lane 2) MEKI 
is not shifted in lysates of PAO-treated cells compared to 
those of growth-arrested control cells (Fig. 3B, lane 1). A 
mobility shift of MEK1 like that seen in lysates of mitogen- 
stimulated cells (Fig. 3B, lanes 3 and 4) has been shown earlier 
to correlate with MEK1 activity [22]. Therefore we concluded 
that MEK1 is not activated in response to PAO and MEKI 
kinase activity is not required for PAO-induced nuclear local- 
ization of ERK1. 
3.4. PAO, in contrast o vanadyl hydroperoxide, does not act 
via general inhibition of tyrosine phosphatases 
Although PAO has been reported to act as a tyrosine phos- 
phatase inhibitor [23-25], no general increase in tyrosine phos- 
phorylation (Fig. 2A, lane 2) and no increase of tyrosine 
phosphorylation of specific proteins was detected. To assess 
whether nuclear localization of ERK1 could still be a conse- 
quence of PAO acting as a tyrosine phosphatase inhibitor, 
another tyrosine phosphatase inhibitor, vanadyl hydroperox- 
ide, was used as an additional control. It is acting similar to 
orthovanadate [26] but it is more potent [27]. Treating cells 
for 10 rain with 100 txM vanadyl hydroperoxide promoted 
nuclear localization of ERK1 comparable to treatment with 
PAO or stimulation with mitogens (Fig. 1, panel A5). Judged 
by immunofluorescence (Fig. 1, panel B5) and Western blot- 
ting (Fig. 2A, lane 5), vanadyl hydroperoxide treatment led to 
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Fig. 1. Localization of ERK1, phosphotyrosine (pY) and DNA (DAPI) (top to bottom) by immunofluorescent staining of REF 52 cells (magni- 
fication 125x). Column 1 shows growth-arrested cells, the cells depicted in the other columns were treated for 10 rain at 37°C as follows: 
2:40/aM PAO, 3:30 ng/ml PDGF BB, 4: 20% FCS, 5:100 l.tM vanadyl hydroperoxide. 
Fig. 2. Tyrosine phosphorylation a d ERK1 activity. The cells analyzed in lanes 1-5 were treated as described for columns I-5 of Fig. 1. The 
autoradiogramm in panel C shows the result of a MAPkinase activity assay for ERK1 activity. 
Fig. 3. A: Localization of ERK1 (top) and check for NARaf expression (bottom) in REF 52 cells microinjected with an expression plasmid 
coding for NARaf by immunofluorescent staining (magnification 125×). B: MEKI phosphorylation detected as reduced mobility in SDS 
PAGE by Western blotting. Treatment of cells used for lysates in lanes 1-5 was as described for columns 1 5 in Fig. 1. 
Fig. 4. In panels A-D (magnification 200 X) the presence or absence of microtubules was determined by indirect immunofluorescence with the 
anti-tubulin antibody IA2 (T.E. Kreis, Geneva). The cells in panels C.1 and D.I were stained against ERKI and panels C.2 and D.2 show the 
same fields stained with the DNA binding dye DAPI (magnification 125× ). All cells were growth-arrested like for panel A, cells for panels C, 
C.1 and C.2 were treated additionally with 8 /aM nocodazole for 30 min at 37°C. The cells for panel B were treated for 10 rain with 40 /aM 
PAO and the cells for panels D, D.I and D.2 were first incubated with 10 [aM taxol for 30 rain and then treated with 40/aM PAO for 10 rain. 
a significant increase in total tyrosine phosphorylation as re- 
ported previously [13]. As a consequence of such phosphoryl- 
ation, ERK1 and ERK2 had a reduced mobility in SDS 
PAGE (Fig. 2B, lane 5). Gel retardation and activation of 
ERK has also been reported in response to treatment with 
the less potent orthovanadate [28], REF52 cells, however, 
showed no increase in phosphotyrosine content when treated 
for 10 min with 1 mM orthovanadate or 1 mM hydrogen 
peroxide (data not shown). 
Although MEK1 mobility shift is due to serine phosphoryl- 
ation alone, MEK1 mobility was reduced in response to 
vanadyl hydroperoxide (Fig. 3B, lane 5). This indicates that 
inhibition of tyrosine phosphatases maintains at least one sig- 
nal transduction pathway which can lead to MEK1 phospho- 
rylation in an activated state. 
Taken together, PAO acts in a different way than a general 
tyrosine phosphatase inhibitor, although involvement of a 
specific phosphatase cannot be excluded at this point. 
3.5. Depolymerization f microtubules by thiol-reactive 
compounds i  not the cause for ERKI translocation 
While stimulation by mitogens did not affect microtubules 
(data not shown), PAO treatment was associated with micro- 
tubule depolymerization (Fig. 4B). It is known that thiol-re- 
active compounds can inhibit microtubule polymerization i
vitro by directly modifying tubulin at cysteins [29]. The actin 
cytoskeleton on the other hand was affected neither by PAO 
nor by mitogens (data not shown). 
Depolymerization f microtubules induced by nocodazole 
(Fig. 4C) demonstrated that disruption of microtubules alone 
did not alter ERKI localization in growth-arrested cells (Fig. 
4C.1). By stabilizing microtubules with taxol to prevent depo- 
lymerization by PAO (Fig. 4D), it was possible to show that 
depolymerization f the microtubule network was not re- 
quired for relocalization of ERK1 to the nucleus by PAO 
(Fig. 4D.I). 
4. Discussion 
Our experiments show that ERK1 can be induced to trans- 
locate to the nucleus in the absence of both activation and the 
upstream signals usually required for activation. Nuclear 
translocation i  response to thiol-modifying chemicals was 
indistinguishable from that following mitogenic stimulation 
of fibroblasts when studied by immunofluorescence. 
NEM, diamide and PAO, the three thiol-reactive chemicals 
used in this study, are structurally very different. Therefore, it 
can be assumed that their shared reactivity towards thiols 
alone is causing ERK1 translocation. Diamide [30] and 
NEM react with mono- and dithiols while PAO preferentially 
bridges covalently between two vicinal or adjacent thiol 
groups [31] found in protein motifs like -CXXC-. Since 
PAO is as effective as the other two chemicals in inducing 
translocation, it is likely that a reaction with a protein con- 
taining such a dithiol is involved. 
ERKs neither contain a nuclear localization signal [32] nor 
one of the recently described nuclear export signals [33] which 
could determine their localization. Since they are small 
enough to enter the nucleus by passive diffusion across nucle- 
ar pores, a mechanism to prevent nuclear localization in un- 
stimulated cells has to be proposed. Such a mechanism could 
be based on one of the two following principles: (1) a cyto- 
plasmic anchor etaining ERK1 in the cytoplasm or (2) active 
export clearing ERK1 from the nucleus. The available data do 
not allow discrimination between these two possibilities. 
To allow translocation i stimulated cells, the localization 
machinery has to be inactivated. We have demonstrated that 
the kinase activity of Raf is required for mediating this event 
in response to serum. Raf could inactivate components of the 
putative localization machinery by direct phosphorylation r 
indirectly via activation of MEK or ERK. 
Since PAO, in contrast o vanadyl hydroperoxide, did not 
activate the MAPK cascade, it can be excluded that it works 
by simply mimicking mitogenic stimulation. We suggest there- 
fore that direct modification of proteins regulating ERK lo- 
calization is the most likely mechanism by which thiol-mod- 
ifying reagents induce ERK1 translocation. 
No potential target involved in an active nuclear export 
mechanism for ERK1 is known. However, a candidate com- 
ponent for a cytoplasmic retention mechanism is found in the 
yeast mating pheromone pathway, the STE5 gene product. 
The STE5 protein (STE5p) has been shown to bind all mem- 
bers of the particular yeast MAPK cascade transmitting the 
pheromone signal [34]. It thus tethers the components to- 
gether and may thereby localize the yeast homologue of 
ERK to the cytoplasm. The general relevance of STE5p as 
a candidate cytoplasmic anchor is unclear since no homologue 
has been found so far in other organisms. 
Alternatively cytoplasmic anchoring of ERK could be 
achieved by direct binding of the kinases of the MAPK cas- 
cade to each other. Supporting such a concept is the fact that 
Ras, Raf and MEK can form a stable complex [19]. In addi- 
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tion, interaction between a member of the MEK family, 
MEK5 and the corresponding member of the ERK family, 
ERK5, has been demonstrated using the two hybrid system 
[35]. Although attractive conceptually since such a complex 
comprising the whole cascade could explain the localization 
of ERK and link its regulation to changes in protein protein 
affinities upon mitogen stimulation, its existence and relevance 
for localization awaits experimental demonstration. 
Microtubule association has been reported for a subpopu- 
lation of ERK which remains in the cytoplasm after mitogen 
stimulation of fibroblasts [36]. A similar interaction with cy- 
toskeletal proteins might contribute to the localization of the 
subpopulation of ERK susceptible to translocation. Our ob- 
servation that nocodazole had no influence on ERKI  locali- 
zation cannot rule out this possibility although it makes an 
involvement of microtubules unlikely. 
Allowing the separation of activation and translocation of 
ERK, the thiol-modifying chemicals used in this study are 
tools that can be used to define in more detail the conditions 
for nuclear translocation of ERK1. Having the most limited 
reactivity towards thiol groups while still fully active in induc- 
ing translocation, PAO could serve to chemically modify and 
subsequently isolate proteins involved in ERK localization. 
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